Watch Video Now Icon WATCH NOW: Clinical experience with ALPROLIX

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX

Please call 1-800-745-4447, Option 5, or complete the form below. The information you provide will be maintained in accordance with our privacy policy .

What information are you interested in learning more about? (Choose all that apply.)


How would you like to be contacted?


By submitting the following information, you are acknowledging that you understand that the information you provide may be used by Sanofi Genzyme and their affiliates, and the business service companies working with Sanofi Genzyme to provide you with additional communications and to develop products and services, which may include market research.

Sanofi Genzyme respects your interest in keeping your personal health information private. We will not sell or rent your information to any third parties or outside mailing lists. For more information on our use of information, see our privacy policy.

Click here to unsubscribe from our mailing list, or call 1-800-207-8049.

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

  • ALPROLIX is contraindicated in patients who have a known history of hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

WARNINGS AND PRECAUTIONS:

  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with factor replacement therapies, and have been reported with ALPROLIX. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment.
  • Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX. Patients using ALPROLIX should be monitored for the development of Factor IX inhibitors. Clotting assays (e.g., one-stage) may be used to confirm that adequate Factor IX levels have been achieved and maintained.
  • The use of Factor IX products has been associated with the development of thromboembolic complications.
  • Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with Factor IX inhibitors and a history of allergic reactions to Factor IX. The safety and efficacy of using ALPROLIX for immune tolerance induction have not been established.

ADVERSE REACTIONS:

  • The most common adverse reactions (incidence ≥1%) in previously untreated patients were injection site erythema, hypersensitivity, and Factor IX inhibition. The most common adverse reactions (incidence ≥1%) in previously treated patients were headache, oral paresthesia, and obstructive uropathy.

INDICATION:

ALPROLIX® is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and children with hemophilia B for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use
ALPROLIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.